Trial Profile

A Phase 2a Study to Evaluate Microglial Activation, Safety, and Clinical Effects of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Foralumab (Primary)
Indications Multiple system atrophy
Focus Therapeutic Use

Most Recent Events

23 Sep 2025 Status changed from not yet recruiting to recruiting.
14 Aug 2025 According to Tiziana Life Sciences media release, the first participant has been enrolled and dosed in this phase 2a clinical trial evaluating intranasal foralumab in patients living with Multiple System Atrophy (MSA) at Brigham and Women's Hospital in Boston, Massachusetts.
11 Aug 2025 According to Tiziana Life Sciences media release, Vikram Khurana MD PhD is the principal investigator of this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com